Skip to main content

Latest Articles

Latest Articles

Showing 9 / 872 Weight Management articles

FDA Proposes Curbs on Compounding Weight-Loss Drugs
Health Policy

FDA Proposes Curbs on Compounding Weight-Loss Drugs

The U.S. Food and Drug Administration (FDA) has proposed a significant change that could reshape the landscape of weight-loss drug accessibility. By suggesting the exclusion of key active ingredients from the list of drugs that outsourcing facilities can compound in bulk, the FDA aims to curb large-scale, unauthorized production of popular medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound).

Shotlee··7 min read